Aytu BioScience to Provide Fiscal First Quarter 2017 Business Update
ENGLEWOOD, Colo., Nov. 3, 2016 /PRNewswire/ -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced today that the company will present its operational results for the first quarter of fiscal 2017 on Monday, November 7, 2016, at 4:30 p.m. ET. The company will review recent accomplishments and provide an overview of its business and growth strategy, as well as its financial results for the fiscal quarter ended September 30, 2016.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- 1 (855) 656-0926 (U.S.)
- 1 (412) 542-4198 (international)
The webcast will be accessible live and archived on Aytu's website, aytubio.com, for 90 days.
A replay of the call will be available for seven days. Access the replay by calling 1 (877) 344-7529 (U.S.) or 1 (412) 317-0088 (international) and using the replay access code 10096080.
About Aytu BioScience, Inc. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. The company currently markets three products: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging, and Primsol® (trimethoprim hydrochloride), the only FDA-approved trimethoprim-only oral solution for urinary tract infections. Additionally, Aytu is developing MiOXSYS™, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared product, and Aytu is conducting U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating urology products, leveraging its focused commercial team and expertise to build leading brands within well-established markets. For more information visit aytubio.com.
For Investors & Media:Tiberend Strategic Advisors, Inc.Joshua Drumm, Ph.D.: firstname.lastname@example.org; (212) 375-2664Janine McCargo: email@example.com; (646) 604-5150
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aytu-bioscience-to-provide-fiscal-first-quarter-2017-business-update-300355774.html
SOURCE Aytu BioScience Inc.